Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2011 (2011), Article ID 351950, 7 pages
http://dx.doi.org/10.1155/2011/351950
Review Article

Antibody-Mediated Rejection in Heart Transplantation: Case Presentation with a Review of Current International Guidelines

1Department of Surgery, Division of Cardiothoracic Surgery, Mayo Clinic Arizona, 5777 E. Mayo Boulevard, Phoenix, AZ 85054, USA
2Department of Medicine, Division of Cardiology, Mayo Clinic Arizona, 5777 E. Mayo Boulevard, Phoenix, AZ 85054, USA
3Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 5777 E. Mayo Boulevard, Phoenix, AZ 85054, USA

Received 16 March 2011; Revised 29 August 2011; Accepted 14 September 2011

Academic Editor: Martin Cadeiras

Copyright © 2011 Octavio E. Pajaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Kobashigawa, M. G. Crespo-Leiro, S. M. Ensminger et al., “Report from a consensus conference on antibody-mediated rejection in heart transplantation,” Journal of Heart and Lung Transplantation, vol. 30, no. 3, pp. 252–269, 2011. View at Publisher · View at Google Scholar · View at PubMed
  2. C. C. Marboe, M. Billingham, H. Eisen et al., “Nodular endocardial infiltrates (quilty lesions) cause significant variability in diagnosis of ISHLT grade 2 and 3A rejection in cardiac allograft recipients,” Journal of Heart and Lung Transplantation, vol. 24, no. 7, pp. S219–S226, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. M. C. Deng, H. J. Eisen, M. R. Mehra et al., “Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling,” American Journal of Transplantation, vol. 6, no. 1, pp. 150–160, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. R. C. Starling, M. Pham, H. Valantine et al., “Molecular testing in the management of cardiac transplant recipients: initial clinical experience,” Journal of Heart and Lung Transplantation, vol. 25, no. 12, pp. 1389–1395, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. X. Pham, J. J. Teuteberg, A. G. Kfoury et al., “Gene-expression profiling for rejection surveillance after cardiac transplantation,” The New England Journal of Medicine, vol. 362, no. 20, pp. 1890–1900, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. R. Mehra and J. Parameshwar, “Gene expression profiling and cardiac allograft rejection monitoring: is IMAGE just a mirage?” Journal of Heart and Lung Transplantation, vol. 29, no. 6, pp. 599–602, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. G. Kfoury, J. Stehlik, D. G. Renlund et al., “Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns,” Journal of Heart and Lung Transplantation, vol. 25, no. 11, pp. 1277–1282, 2006. View at Publisher · View at Google Scholar · View at PubMed
  8. A. G. Kfoury, M. E. Hammond, G. L. Snow et al., “Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection,” Journal of Heart and Lung Transplantation, vol. 28, no. 8, pp. 781–784, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. O. Taylor, R. L. Yowell, A. G. Kfoury, E. H. Hammond, and D. G. Renlund, “Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection,” Journal of Heart and Lung Transplantation, vol. 19, no. 6, pp. 518–521, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. A. G. Kfoury and M. E. Hammond, “Controversies in defining cardiac antibody-mediated rejection: need for updated criteria,” Journal of Heart and Lung Transplantation, vol. 29, no. 4, pp. 389–394, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. P. Revelo, J. Stehlik, D. Miller et al., “Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death?” Journal of Heart and Lung Transplantation, vol. 30, no. 2, pp. 144–150, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. E. R. Rodriguez and C. D. Tan, “Pathologic evaluation for antibody-mediated rejection: prognostic vs diagnostic markers?” Journal of Heart and Lung Transplantation, vol. 30, no. 2, pp. 136–138, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. S. Stewart, G. L. Winters, M. C. Fishbein et al., “Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection,” Journal of Heart and Lung Transplantation, vol. 24, no. 11, pp. 1710–1720, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. G. W. Wu, J. A. Kobashigawa, M. C. Fishbein et al., “Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes,” Journal of Heart and Lung Transplantation, vol. 28, no. 5, pp. 417–422, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. Kobashigawa, K. K. Kiyosaki, J. K. Patel et al., “Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes,” Journal of Heart and Lung Transplantation, vol. 29, no. 5, pp. 504–508, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. B. Sis, G. S. Jhangri, S. Bunnag, K. Allanach, B. Kaplan, and P. F. Halloran, “Endothelial gene expression in kidney transplants with alloantibody indicates Antibody-mediated damage despite lack of C4d staining,” American Journal of Transplantation, vol. 9, no. 10, pp. 2312–2323, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. B. Sis and P. F. Halloran, “Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection,” Current Opinion in Organ Transplantation, vol. 15, no. 1, pp. 42–48, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. B. A. Pisani, G. M. Mullen, K. Malinowska et al., “Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation,” Journal of Heart and Lung Transplantation, vol. 18, no. 7, pp. 701–706, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. S. C. Jordan, A. W. Quartel, L. S. Czer et al., “Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral reaction in renal and cardiac allograft recipients and potential mechanism of action,” Transplantation, vol. 66, no. 6, pp. 800–808, 1998. View at Google Scholar · View at Scopus
  20. P. N. Rocha, D. W. Butterly, A. Greenberg et al., “Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection,” Transplantation, vol. 75, no. 9, pp. 1490–1495, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. R. W. Lehrich, P. N. Rocha, N. Reinsmoen et al., “Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation,” Human Immunology, vol. 66, no. 4, pp. 350–358, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. E. R. Rodriguez, D. V. Skojec, C. D. Tan et al., “Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers,” American Journal of Transplantation, vol. 5, no. 11, pp. 2778–2785, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. Shah, T. Nadasdy, L. Arend et al., “Treatment of C4D-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin,” Transplantation, vol. 77, no. 9, pp. 1399–1405, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Kobashigawa, L. W. Miller, S. D. Russell et al., “Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-Year report,” American Journal of Transplantation, vol. 6, no. 6, pp. 1377–1386, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. I. C. Balfour, A. Fiore, R. J. Graff, and A. P. Knutsen, “Use of rituximab to decrease panel-reactive antibodies,” Journal of Heart and Lung Transplantation, vol. 24, no. 5, pp. 628–630, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. I. Kaczmarek, M. A. Deutsch, S. Sadoni et al., “Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review,” Journal of Heart and Lung Transplantation, vol. 26, no. 5, pp. 511–515, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. H. E. Garrett Jr., D. Duvall-Seaman, B. Helsley, and K. Groshart, “Treatment of vascular rejection with rituximab in cardiac transplantation,” Journal of Heart and Lung Transplantation, vol. 24, no. 9, pp. 1337–1342, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. M. J. Everly, J. J. Everly, B. Susskind et al., “Bortezomib provides effective therapy for antibody—and cell-mediated acute rejection,” Transplantation, vol. 86, no. 12, pp. 1754–1761, 2008. View at Publisher · View at Google Scholar · View at PubMed
  29. M. J. Everly, J. J. Everly, B. Susskind et al., “Proteasome inhibition reduces donor-specific antibody levels,” Transplantation Proceedings, vol. 41, no. 1, pp. 105–107, 2009. View at Publisher · View at Google Scholar · View at PubMed
  30. C. J. Parker, S. Kar, and P. Kirkpatrick, “Eculizumab,” Nature Reviews Drug Discovery, vol. 6, no. 7, pp. 515–516, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. C. Parker, “Eculizumab for paroxysmal nocturnal haemoglobinuria,” The Lancet, vol. 373, no. 9665, pp. 759–767, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. P. Salter, M. M. Salter, J. K. Kirklin, R. C. Bourge, and D. C. Naftel, “Total lymphoid irradiation in the treatment of early or recurrent heart transplant rejection,” International Journal of Radiation Oncology Biology Physics, vol. 33, no. 1, pp. 83–88, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. J. K. Kirklin, R. N. Brown, S. T. Huang et al., “Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis,” Journal of Heart and Lung Transplantation, vol. 25, no. 3, pp. 283–288, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus